Plesner Advises the LEO Foundation and LEO Pharma in Connection with €450 Million Investment
March, 2021 - Denmark
Accura advised Nordic Capital, while Plesner has advised the LEO Foundation and LEO Pharma in connection with the investment.
The private equity investor Nordic Capital invested EUR 450m in LEO Pharma. Nordic Capital becomes an active minority owner and will partner with LEO Pharma’s majority owner the LEO Foundation.
LEO Pharma is a global leader in medical dermatology. The investment will strengthen the company’s market position and help accelerate innovation and growth through upcoming product launches as well as continued focus on LEO Pharma’s market-leading established product portfolio. LEO Pharma is headquartered in Denmark with a global team of 6,000 employees, serving 93 million patients in more than 130 countries.
The LEO Foundation is one of Denmark’s largest commercial foundations and the controlling owner of LEO Pharma. Nordic Capital is an active, experienced and leading private equity investor with a strong Scandinavian heritage. Nordic Capital will invest EUR 450 million in LEO Pharma and partner up with the LEO Foundation to support the company’s 2030 strategy to be a global leader in medical dermatology. The LEO Foundation will remain the company’s majority shareholder and Nordic Capital will be an active minority shareholder.
Since its inception in 1989, Nordic Capital has invested in 29 healthcare companies across Europe and North America. Today, the investor has 14 portfolio companies in the broader healthcare sector.
The Accura team was led by Kristian Lykkeholm Klausen (Picture) and Thomas Weincke and further included Morten Bruus, Christoffer Ege Andersen, Thomas Stenholt Engmann, Camilla Martekilde and Martin Frank Madsen.
The Plesner team was headed by Lars Bunch,Thomas Holst Laursen and Hans Hedegaard together with Morten Stig Ottesen, Sara Hanquist Johnsen and Nina Charlotte Vestergaard.
